TY - JOUR
T1 - Escape from Pluripotency via Inhibition of TGF-β/BMP and Activation of Wnt Signaling Accelerates Differentiation and Aging in hPSC Progeny Cells
AU - Fujimori, Koki
AU - Matsumoto, Takuya
AU - Kisa, Fumihiko
AU - Hattori, Nobutaka
AU - Okano, Hideyuki
AU - Akamatsu, Wado
N1 - Funding Information:
We are grateful to Prof. Douglass Sipp (Keio University) for providing invaluable comments on the manuscript and to all the members of the H.O. laboratory for their encouragement and kind support. We also would like to thank N. Nakatsuji and H. Suemori (Kyoto University) for providing hESC clones and S. Yamanaka and M. Nakagawa (Kyoto University) for donating hiPSC clones (201B7). This work was supported by funding from the Research Project for Practical Applications of Regenerative Medicine from Japan Agency for Medical Research and Development (AMED) (grant nos. 15bk0104027h0003 , 16bk0104016h0004 to H.O.), the Research Center Network for Realization Research Centers/Projects of Regenerative Medicine (the Program for Intractable Disease Research utilizing disease-specific iPSCs) from the Japan Science and Technology Agency (JST) and AMED (grant nos. 12033011 , 15bm0609003h0004 , 16bm0609003h0005 to W.A. and H.O.), the New Energy and Industrial Technology Development Organization (NEDO) (grant no. 17be0204436h0004 to W.A. and H.O.), the Japan Society for the Promotion of Science (JSPS) (grant no. JP16K09677 to W.A.), Research Fellowships of Japan Society for the Promotion of Science for Young Scientists (grant no. JP16J06437 to K.F.), the Keio University Grant-in-Aid for the Encouragement of Young Medical Scientists (to K.F.), the Keio University Doctorate Student Grant-in-Aid Program (to K.F.) and a Grant-in-Aid for the Global COE Program from MEXT to Keio University. H.O. is a paid Scientific Advisory Board Member at SanBio Co., Ltd. and K Pharma Inc.
Funding Information:
We are grateful to Prof. Douglass Sipp (Keio University) for providing invaluable comments on the manuscript and to all the members of the H.O. laboratory for their encouragement and kind support. We also would like to thank N. Nakatsuji and H. Suemori (Kyoto University) for providing hESC clones and S. Yamanaka and M. Nakagawa (Kyoto University) for donating hiPSC clones (201B7). This work was supported by funding from the Research Project for Practical Applications of Regenerative Medicine from Japan Agency for Medical Research and Development (AMED) (grant nos. 15bk0104027h0003, 16bk0104016h0004 to H.O.), the Research Center Network for Realization Research Centers/Projects of Regenerative Medicine (the Program for Intractable Disease Research utilizing disease-specific iPSCs) from the Japan Science and Technology Agency (JST) and AMED (grant nos. 12033011, 15bm0609003h0004, 16bm0609003h0005 to W.A. and H.O.), the New Energy and Industrial Technology Development Organization (NEDO) (grant no. 17be0204436h0004 to W.A. and H.O.), the Japan Society for the Promotion of Science (JSPS) (grant no. JP16K09677 to W.A.), Research Fellowships of Japan Society for the Promotion of Science for Young Scientists (grant no. JP16J06437 to K.F.), the Keio University Grant-in-Aid for the Encouragement of Young Medical Scientists (to K.F.), the Keio University Doctorate Student Grant-in-Aid Program (to K.F.) and a Grant-in-Aid for the Global COE Program from MEXT to Keio University. H.O. is a paid Scientific Advisory Board Member at SanBio Co., Ltd. and K Pharma Inc.
Publisher Copyright:
© 2017 The Authors
PY - 2017/11/14
Y1 - 2017/11/14
N2 - Human pluripotent stem cells (hPSCs) represent a potentially valuable cell source for applications in cell replacement therapy, drug development, and disease modeling. For all these uses, it is necessary to develop reproducible and robust protocols for differentiation into desired cell types. However, differentiation protocols remain unstable and inefficient, which makes minimizing the differentiation variance among hPSC lines and obtaining purified terminally differentiated cells extremely time consuming. Here, we report a simple treatment with three small molecules—SB431542, dorsomorphine, and CHIR99021—that enhanced hPSC differentiation into three germ layers with a chemically transitional embryoid-body-like state (CTraS). Induction of CTraS reduced the innate differentiation propensities of hPSCs (even unfavorably differentiated hPSCs) and shifted their differentiation into terminally differentiated cells, particularly neurons. In addition, CTraS induction accelerated in vitro pathological expression concurrently with neural maturation. Thus, CTraS can promote the latent potential of hPSCs for differentiation and potentially expand the utility and applicability of hPSCs. Simple treatment with three small molecules enhanced hPSC differentiation into three germ layers, namely CTraS. CTraS reduced the innate differentiation propensities of hPSCs and shifted them into terminal differentiations. CTraS induction accelerated in vitro pathological expression with maturation and aging. Thus, CTraS can bring out the latent potential of hPSCs.
AB - Human pluripotent stem cells (hPSCs) represent a potentially valuable cell source for applications in cell replacement therapy, drug development, and disease modeling. For all these uses, it is necessary to develop reproducible and robust protocols for differentiation into desired cell types. However, differentiation protocols remain unstable and inefficient, which makes minimizing the differentiation variance among hPSC lines and obtaining purified terminally differentiated cells extremely time consuming. Here, we report a simple treatment with three small molecules—SB431542, dorsomorphine, and CHIR99021—that enhanced hPSC differentiation into three germ layers with a chemically transitional embryoid-body-like state (CTraS). Induction of CTraS reduced the innate differentiation propensities of hPSCs (even unfavorably differentiated hPSCs) and shifted their differentiation into terminally differentiated cells, particularly neurons. In addition, CTraS induction accelerated in vitro pathological expression concurrently with neural maturation. Thus, CTraS can promote the latent potential of hPSCs for differentiation and potentially expand the utility and applicability of hPSCs. Simple treatment with three small molecules enhanced hPSC differentiation into three germ layers, namely CTraS. CTraS reduced the innate differentiation propensities of hPSCs and shifted them into terminal differentiations. CTraS induction accelerated in vitro pathological expression with maturation and aging. Thus, CTraS can bring out the latent potential of hPSCs.
KW - aging
KW - differentiation
KW - disease model
KW - induced pluripotent stem cells
KW - pluripotency
KW - stem cell biotechnology
KW - stem cell differentiation
UR - http://www.scopus.com/inward/record.url?scp=85032588341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032588341&partnerID=8YFLogxK
U2 - 10.1016/j.stemcr.2017.09.024
DO - 10.1016/j.stemcr.2017.09.024
M3 - Article
C2 - 29107593
AN - SCOPUS:85032588341
SN - 2213-6711
VL - 9
SP - 1675
EP - 1691
JO - Stem cell reports
JF - Stem cell reports
IS - 5
ER -